Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients

Trial Profile

A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTI-125 (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Pharmacokinetics
  • Sponsors Cassava Sciences
  • Most Recent Events

    • 09 Sep 2019 Results presented in the Cassava Sciences media release.
    • 09 Sep 2019 According to an Cassava Sciences Media Release, the company expects to present full data sets from this trial at Clinical Trials on Alzheimer's Disease (CTAD), a conference for the medical and scientific community being held in San Diego, CA, December 4-7th, 2019.
    • 09 Sep 2019 According to an Cassava Sciences Media Release, this study was supported by the National Institute on Aging at NIH under award AG060878.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top